ArticleCerebellum (London, England)2014
Consensus paper: management of degenerative cerebellar disorders.
Article in Cerebellum (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 209 citations in OpenAlex.
- The Effectiveness of Virtual Reality-Based Interventions in Patients with Ataxic Conditions: A Systematic Review with Meta-Analysis.Sensors (Basel, Switzerland) · 2026Pooled it
- Exercise and Physical Therapy Interventions for Children with Ataxia: A Systematic Review.Cerebellum (London, England) · 2019Pooled it
- Gait training with a wearable curara® robot for cerebellar ataxia: a single-arm study.Biomedical engineering online · 2021Trial
- Trial
- The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort.CNS drugs · 2026Article
- Management of fragile X-associated tremor ataxia syndrome: a review for clinicians.Frontiers in neurology · 2026Review
- First Application of a Novel Brain Template: Motor Training Improves Cortico-cerebellar Connectivity in Cerebellar Ataxia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Impact of rehabilitation on quality of life in patients with degenerative cerebellar ataxias using structural equation modeling.Scientific reports · 2025Article
- Cerebellar re-irradiation after whole brain radiotherapy significant symptom relief with minimal toxicity in metastatic brain patients.Scientific reports · 2025Article
- Fatigue Limits Motor and Cognitive Improvements after High-intensity Exercise Prior to Balance Training over Telehealth in People with Spinocerebellar Ataxia.International journal of telerehabilitation · 2025Article
- Quantification of Solid Embryonic Cerebellar Graft Volume in a Degenerative Ataxia Model.Cerebellum (London, England) · 2024Article
- Local Dynamic Stability of Trunk During Gait is Responsive to Rehabilitation in Subjects with Primary Degenerative Cerebellar Ataxia.Cerebellum (London, England) · 2024Article
- Reinforcement Motor Learning After Cerebellar Damage Is Related to State Estimation.Cerebellum (London, England) · 2024Article
- Primary Coenzyme Q10 Deficiency-Related Ataxias.Journal of clinical medicine · 2024Review
- [Scale for the assessment and rating of ataxia (SARA): translation and cultural adaptation to German-speaking areas].Wiener medizinische Wochenschrift (1946) · 2024Article
- Patient pathways for rare diseases in Europe: ataxia as an example.Orphanet journal of rare diseases · 2023Article
- A De Novo HECW2 Variant in a Patient with Acetazolamide-Responsive Episodic Ataxia.Cerebellum (London, England) · 2023Article
- Symptomatic Care in Multiple System Atrophy: State of the Art.Cerebellum (London, England) · 2023Review
- Mechanisms underlying phenotypic variation in neurogenetic disorders.Nature reviews. Neurology · 2023Review
- Therapeutic Strategies for Spinocerebellar Ataxia Type 1.Biomolecules · 2023Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
Abstract
Treatment of motor symptoms of degenerative cerebellar ataxia remains difficult. Yet there are recent developments that are likely to lead to significant improvements in the future. Most desirable would be a causative treatment of the underlying cerebellar disease. This is currently available only for a very small subset of cerebellar ataxias with known metabolic dysfunction. However, increasing knowledge of the pathophysiology of hereditary ataxia should lead to an increasing number of medically sensible drug trials. In this paper, data from recent drug trials in patients with recessive and dominant cerebellar ataxias will be summarized. There is consensus that up to date, no medication has been proven effective. Aminopyridines and acetazolamide are the only exception, which are beneficial in patients with episodic ataxia type 2. Aminopyridines are also effective in a subset of patients presenting with downbeat nystagmus. As such, all authors agreed that the mainstays of treatment of degenerative cerebellar ataxia are currently physiotherapy, occupational therapy, and speech therapy. For many years, well-controlled rehabilitation studies in patients with cerebellar ataxia were lacking. Data of recently published studies show that coordinative training improves motor function in both adult and juvenile patients with cerebellar degeneration. Given the well-known contribution of the cerebellum to motor learning, possible mechanisms underlying improvement will be outlined. There is consensus that evidence-based guidelines for the physiotherapy of degenerative cerebellar ataxia need to be developed. Future developments in physiotherapeutical interventions will be discussed including application of non-invasive brain stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.